Circulation, Vol 88, 364-371, Copyright © 1993 by American Heart Association
RJ Rodeheffer, M Naruse, JB Atkinson, K Naruse, JC Burnett Jr, WH Merrill, WH Frist, H Demura and T Inagami
BACKGROUND. Atrial natriuretic factor (ANF) is produced by myocardial
tissue, and the plasma ANF concentration is known to be elevated in
congestive heart failure (CHF). Data from animal models indicate that
myocardial concentrations of ANF are depleted in CHF, and this has given
rise to the hypothesis that CHF is characterized by depletion of stored
ANF. To date, the molecular forms of ANF and their concentrations in atrial
and ventricular myocardium remain poorly characterized in the normal and
the failing human heart. METHODS AND RESULTS. We measured ANF
concentrations in fresh tissue from failing human hearts explanted at the
time of cardiac transplantation and from organ donors whose normal hearts
could not be used for transplantation. We determined total ANF and alpha,
beta, and gamma ANF concentrations in the right and left atrial appendages,
atrial free walls, and ventricles. In normal hearts, ANF concentration in
the atrial appendages was 40-fold higher than ANF in the rest of the atrial
free wall and in the ventricles. In the failing hearts, atrial appendage
ANF concentrations increased 5- to 10-fold, and atrial free wall ANF
concentrations increased 200-fold. Analysis of molecular forms of ANF
demonstrated significant increases in the gamma and beta forms in the left
atrial appendage of failing hearts. alpha, beta, and gamma ANF forms were
also significantly increased in right and left atrial free wall tissue from
failing hearts. In addition, failing hearts were characterized by absolute
and relative increases in the precursor form gamma ANF. CONCLUSIONS. These
data from fresh tissues suggest that cardiac ANF stores are not decreased
in severe CHF in humans; rather, chronic CHF is characterized by marked
increases in atrial ANF tissue concentrations, particularly the beta and
gamma ANF forms. These findings are consistent with intracellular
accumulation of precursor ANF forms in severe chronic human CHF.
ARTICLES
Molecular forms of atrial natriuretic factor in normal and failing human myocardium
Department of Medicine, Mayo Clinic, Rochester, Minn 55905.
This article has been cited by other articles:
![]() |
C. Stollberger, B. Schneider, and J. Finsterer Elimination of the Left Atrial Appendage To Prevent Stroke or Embolism?: Anatomic, Physiologic, and Pathophysiologic Considerations Chest, December 1, 2003; 124(6): 2356 - 2362. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kimura, K. Takahashi, K. Totsune, Y. Muramatsu, C. Kaneko, A. D. Darnel, T. Suzuki, M. Ebina, T. Nukiwa, and H. Sasano Expression of Urocortin and Corticotropin-Releasing Factor Receptor Subtypes in the Human Heart J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 340 - 346. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Yoshihara, T. Nishikimi, Y. Sasako, J. Kobayashi, Y. Kosakai, R. Hattori, T. Horio, S. Kitamura, H. Matsuo, T. Ohe, et al. PRESERVATION OF THE RIGHT ATRIAL APPENDAGE IMPROVES REDUCED PLASMA ATRIAL NATRIURETIC PEPTIDE LEVELS AFTER THE MAZE PROCEDURE J. Thorac. Cardiovasc. Surg., April 1, 2000; 119(4): 790 - 794. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Doyama, M. Fukumoto, G. Takemura, M. Tanaka, T. Oda, K. Hasegawa, T. Inada, S. Ohtani, T. Fujiwara, H. Itoh, et al. Expression and distribution of brain natriuretic peptide in human right atria J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1832 - 1838. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Yoshihara, T. Nishikimi, Y. Kosakai, F. Isobe, H. Matsuoka, S. Takishita, Y. Kawashima, Y. Saito, H. Matsuo, and K. Kangawa Atrial natriuretic peptide secretion and body fluid balance after bilateral atrial appendectomy by the maze procedure J. Thorac. Cardiovasc. Surg., August 1, 1998; 116(2): 213 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. James, P. M. McCarthy, S. Jaalouk, E. L. Bravo, A. Betkowski, J. D. Thomas, S. Nakatani, and F. M. Fouad-Tarazi Plasma Volume and Its Regulatory Factors in Congestive Heart Failure After Implantation of Long-term Left Ventricular Assist Devices Circulation, April 15, 1996; 93(8): 1515 - 1519. [Abstract] [Full Text] |
||||
![]() |
K. B. James, P. M. McCarthy, J. D. Thomas, R. Vargo, R. E. Hobbs, S. Sapp, and E. Bravo Effect of the Implantable Left Ventricular Assist Device on Neuroendocrine Activation in Heart Failure Circulation, November 1, 1995; 92(9): 191 - 195. [Abstract] [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1993 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |